Clinical Trial Update: TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study [Phase 2]

View source ↗

Summary

Phase 2 results of the TABAsCO study evaluating TAS-102 in combination with irinotecan and bevacizumab for pre-treated metastatic or unresectable colorectal can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Camptosar (irinotecan)
• Lonsurf (trifluridine/tipiracil)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-02-10